Clinical-stage biopharma HBM Holdings Ltd. (also known as Harbour Biomed) debuted on the Hong Kong Stock Exchange on Dec. 10, raising HK$1.71 billion (US$220.7 million) to advance its autoimmune candidates to commercial launches in 2023.
Nothing much has changed since last month. This year is still, by far, the best year for financings in biopharma history, although the gap between 2020 and the next highest year has widened even more.
Chinese biopharma Impact Therapeutics Inc. of Nanjing raised $50 million in a series C+ round on Nov. 30, two years after its $30 million series C round. Impact’s CEO Jun Bao told BioWorld that the majority of the proceeds would be used to take several programs forward. The financing round also paved the way toward an IPO.
HONG KONG – Olix Pharmaceuticals Inc. has raised ₩41.5 billion (US$37.90 million) to support the company’s U.S. expansion and advance its pipeline globally.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Auris Medical, Burning Rock, Canbridge, ILC, I-Mab, Neuroglee, Olix, Perseus Proteomics, Sinovac, Sunshine.
Shenzhen Xbiome Biotech Co. Ltd., an artificial intelligence (AI)-based microbiome drugmaker, raised more than $20 million in a series B+ round, Xbiome CEO Yan Tan told BioWorld, financing that will help the company launch its phase I trial next year. It has been a year since the drugmaker closed a $14 million series B round. During this period, Tan said Xbiome submitted an IND to the FDA in October for its fecal microbiota transplant (FMT) capsule candidate, a potential treatment for graft-vs.-host disease.
HONG KONG – D3 Bio Inc. is the new kid on the biopharma block in Shanghai, kicking off with a $200 million series A financing backed by some of Asia’s most prominent venture capital firms.
HONG KONG – Hutchison China Meditech Ltd. (also known as Chi-Med) has received a $100 million equity investment from the Canada Pension Plan Investment Board, which will fund ongoing research, clinical development and commercialization capabilities.
RSS
